The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 15, 2022

Filed:

Apr. 14, 2017
Applicant:

Berkeley Lights, Inc., Emeryville, CA (US);

Inventors:

Kevin T Chapman, Emeryville, CA (US);

Xiaohua Wang, Pomona, NY (US);

Xiao Guan Radstrom, San Rafael, CA (US);

Yelena Bronevetsky, Alameda, CA (US);

Guido K Stadler, San Francisco, CA (US);

Gregory G Lavieu, Vitry sur Seine, FR;

Annamaria Mocciaro, San Francisco, CA (US);

Assignee:

Berkeley Lights, Inc., Emeryville, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/55 (2006.01); C12N 9/24 (2006.01); C07K 16/28 (2006.01); B01L 3/00 (2006.01); C07K 14/195 (2006.01); C12N 5/0783 (2010.01); A61K 31/65 (2006.01); C12N 5/00 (2006.01); C12N 5/0781 (2010.01); C07K 14/47 (2006.01); C07K 14/52 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 31/65 (2013.01); A61K 39/0011 (2013.01); B01L 3/50273 (2013.01); B01L 3/502761 (2013.01); C07K 14/195 (2013.01); C07K 14/4748 (2013.01); C07K 14/52 (2013.01); C07K 14/55 (2013.01); C07K 16/2818 (2013.01); C12N 5/00 (2013.01); C12N 5/0635 (2013.01); C12N 5/0636 (2013.01); C12N 5/0637 (2013.01); C12N 5/0638 (2013.01); C12N 9/2402 (2013.01); C12Y 302/01166 (2013.01); B01L 2300/0861 (2013.01); B01L 2300/0896 (2013.01); B01L 2400/0424 (2013.01); C07K 2317/14 (2013.01); C07K 2319/00 (2013.01); C12N 2501/04 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.


Find Patent Forward Citations

Loading…